Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 375 results
Press release cover image

Sep 16, 2026

Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery

Antibody characterization data generated by Twist supports TuneLab AI models designed to accelerate antibody discoverySOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody d
Press release cover image

Sep 16, 2026

X-Chem Named First Winner of Chordoma Foundation TBXT Challenge with Discovery of Novel Binder for Untreatable Bone Cancer Target

WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- X-Chem, a pioneer in DNA-Encoded Library (DEL) technology and computational drug discovery, today announced it has won the Chordoma Foundation’s TBXT Challenge, securing $100,000 in milestone awards. The company was the first of 26 participating teams to discover a compound that binds Brachyury (TBXT) below the 1 micromolar threshold. TBXT is a key vulnerability in chordoma, a rare bone cancer with significant unmet treatment need. Winning the
A minimalist illustration of a pill and molecular structure in a dark palette.

Sep 16, 2026

TikTok parent ByteDance raises cash for drug AI spinout Anew

ByteDance has successfully raised $290 million for its AI-driven drug discovery venture, Anew Labs, marking a significant step in the intersection of technology and pharmaceuticals.The funding round was led by prominent investors including HSG, IDG Capital, and Hillhouse Investment, with participation from 5Y Capital. ByteDance maintains a 56% ownership stake in Anew Labs, which was officially spun out as a separate entity in June after being established in 2021. Under the leadership of Liu Kai,
Press release cover image

Sep 16, 2026

Novo and Anthropic will collaborate to advance drug discovery with Claude

Collaboration aims to help Novo discover and develop new medicines faster      Novo will use Anthropic models and Claude Science to advance scientific reasoning for Research and Development (R&D) and agentic software engineeringThis will further build on Novo’s work to become the world’s most AI-driven healthcare company Bagsværd, Denmark, 16 September 2026 – Novo Nordisk and Anthropic today announced a collaboration that will help Novo accelerate the development of new medicines and advanc
A vial of drug compound on a lab bench with chemical reagents in the background.

Sep 16, 2026

AI spots drugs that may be repurposed for priority pathogen

Recent advancements in AI have enabled researchers to identify potential drug candidates that could combat resistant infections caused by Streptococcus pneumoniae, a significant public health threat.Led by Pedro Ballester from Imperial College London, the research team utilized three AI algorithms to analyze nearly 7,000 approved and investigational drugs. These algorithms were trained on existing data regarding drug efficacy against resistant bacteria, resulting in the identification of 11 prom
Press release cover image

Sep 16, 2026

Nona Biosciences Successfully Develops World's First Language Model Trained on Fully Human Heavy-Chain-Only Antibodies

CAMBRIDGE, Mass., Sept. 16, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced the development of HCAbLM, the world's first language model specifically trained on fully human heavy-chain-only antibodies (HCAbs). HCAbLM was built on a large-scale repertoire comprising 31.8 million fully human HCAb sequences from 73 independently immunized HCAb transgenic mice. The stu
A glass vial with a drug compound on a lab bench next to a microscope.

Sep 15, 2026

Magnitude Biosciences secures €1.5 million investment to scale in-vivo drug discovery platform

Magnitude Biosciences has successfully raised €1.5 million to enhance its in vivo drug discovery platform, VivoScan, which aims to revolutionize the screening of compounds in whole organisms.The funding round, led by Northstar Ventures through various funds, also unlocked an additional Innovate UK grant of €253k. Magnitude's CEO, Dr. Fozia Saleem, emphasized the company's goal to be the first to screen millions of compounds within a living organism, thereby significantly accelerating drug discov
Press release cover image

Sep 14, 2026

Inductive Bio launches Indy, an AI chemistry assistant, to double the capacity of every medicinal chemist

Indy is the world's first medicinal chemistry agent. Indy outperforms Claude Opus 5 and GPT-5.6 Sol in head-to-head benchmarks that include QC'ing new assay data, analyzing SAR, and the design/triage of analogs.NEW YORK, Sept. 14, 2026 /PRNewswire/ -- Inductive Bio today launched Indy, an AI chemistry assistant, available to partners now. Inductive's medicinal chemists, computational chemists, and DMPK scientists built Indy for their work inside partner programs, where it has doubled the team's
Press release cover image

Sep 14, 2026

AI-Driven Reactive Modeling Platform QuantaMind Research Published in Science Advances, Advancing a New Paradigm in AI-Powered Molecular R&D

SHANGHAI, Sept. 14, 2026 /PRNewswire/ -- MoleculeMind, an AI-native bioengineering infrastructure company, announced that research on its proprietary AI-driven reactive atomistic modeling platform, QuantaMind, has been published in Science Advances. The study demonstrates that QuantaMind achieves Density Functional Theory (DFT)-level accuracy while enabling tens-of-nanosecond reactive molecular dynamics (MD) simulations of 10,000-atom complex biomolecular systems. As the pioneering platform to s
Press release cover image

Sep 14, 2026

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologiesThe unique capabilities of AI-Immunology™ could potentially help develop new treatments with higher efficacy and less side effects than current treatmentsInitial experimental data will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 202
Press release cover image

Sep 10, 2026

AINN-P1: Small Model, Big Intelligence

AINN-P1: Small Model, Big IntelligenceHow does a 167M-parameter protein foundation model outperform a 650M general-purpose model on the tasks that matter?Ainnocence Inc.,an AI-driven drug discovery company, announced new results for AINN-P1, apurpose-built protein foundation model designed to deliver efficient andtransferable predictions for protein engineering and biologics discovery.AINN-P1 takes a sequence-first approach,generating protein representations directly from amino acid sequences wi
A test tube with a colorful chemical compound in a dimly lit lab

Sep 10, 2026

Novalix and OpenBench partner to deliver AI-validated hit series on fee-for-success basis

Novalix and OpenBench have announced a strategic partnership aimed at revolutionizing the drug discovery process by offering AI-validated chemical hit series through a fee-for-success model.In this collaboration, OpenBench will initially screen vast libraries of compounds, identifying and synthesizing the most promising candidates. These hits will then be handed over to Novalix, which will utilize its in vitro screening capabilities to refine these candidates into actionable starting points for